Amgen Will Tap Experience With ODAC’s EPO Review To Tackle Renal Panel
Executive Summary
Amgen will use experience gained during FDA's Oncologic Drugs Advisory Committee review of the safety of erythropoiesis-stimulating agents to inform its strategy for a similar meeting of the Cardiovascular and Renal Drugs Advisory Committee this fall